Invivyd plans LIBERTY trial comparing VYD2311 tolerability with mRNA COVID vaccine

Invivyd

Invivyd

IVVD

0.00
  • Invivyd posted a MedRxiv preprint analyzing early tolerability from its prior EVADE trial of investigational COVID-19 monoclonal antibody adintrevimab, with results already available.
  • Analysis found minimal short-term systemic side effects versus placebo, supporting a more favorable tolerability profile than vaccination in cross-trial comparisons.
  • Work sets up a near-term start for LIBERTY, a prospective head-to-head trial designed to compare systemic symptoms from low-dose monoclonal antibody candidate VYD2311 versus an mRNA vaccine.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605110701PRIMZONEFULLFEED9717132) on May 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.